NICE TAs

04/05/2020

TA413: Elbasvir–grazoprevir for treating chronic hepatitis C

04/05/2020

TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

04/05/2020

TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea

04/05/2020

TA463: Cabozantinib for previously treated advanced renal cell carcinoma

04/05/2020

TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

04/05/2020

TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

04/05/2020

TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma

01/05/2020

TA456: Ustekinumab for moderately to severely active Crohn's disease after previous treatment

01/05/2020

TA448: Etelcalcetide for treating secondary hyperparathyroidism

01/05/2020

TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

01/05/2020

TA487: Venetoclax for treating chronic lymphocytic leukaemia

01/05/2020

TA443: Obeticholic acid for treating primary biliary cholangitis

01/05/2020

TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

01/05/2020

TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

01/05/2020

TA466: Baricitinib for moderate to severe rheumatoid arthritis

01/05/2020

TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant

30/04/2020

TA485: Sarilumab for moderate to severe rheumatoid arthritis

30/04/2020

TA511: Brodalumab for treating moderate to severe plaque psoriasis

30/04/2020

TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy

29/04/2020

TA480: Tofacitinib for moderate to severe rheumatoid arthritis